(Q36156022)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Understanding the enzymology of fibrinolysis and improving thrombolytic therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Craig Thelwell

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Craig Thelwell

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

7 April 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

3303-3309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15943975%20AND%20SRC:MED&resulttype=core&format=json

Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

New thrombolytic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Third-generation thrombolytic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Thrombolysis: the need for a critical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Bolus fibrinolytic therapy in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

A miniaturized fibrinolytic assay for plasminogen activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasminogen by human urokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

The determination of recombinant human tissue-type plasminogen activator activity by turbidimetry using a microcentrifugal analyzer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

A new euglobulin clot lysis assay for global fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

A plasmin generation method for the determination of tissue plasminogen activator (t-PA) activity in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

International collaborative study to establish the 3rd International Standard for Streptokinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Regulation of tissue plasminogen activator activity by cells. Domains responsible for binding and mechanism of stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Myosin: a noncovalent stabilizer of fibrin in the process of clot dissolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

The ideal fibrinolytic: can drug design improve clinical results?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

One-year follow-up of the ASSENT-2 trial: A double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058

Making cells work — metabolic engineering for everyone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.03.058